Would you offer adjuvant pembrolizumab to a stage II-III adenocarcinoma of the lung who had a complete pathologic response to 4 cycles of cisplatin/pemetrexed/pembro (KN-671)?

Community
Company
News
Contact Us
Sign in

Topics: Thoracic Malignancies • Medical Oncology

And would your answer be different if you had used pre-op nivolumab (CM-816)?

Related Questions

For those early stage resectable NSCLC patients who received neoadjuvant chemoimmunotherapy as per Checkmate816 and did not attain a pCR, what are the adjuvant immunotherapy treatment strategies if EGFR negative?

When do you offer SBRT for a small, slowly growing lung lesion?

Would you offer adjuvant osimertinib in a patient with complete pathologic response to neoadjuvant platinum doublet for a stage IIIA resected EGFR mutant lung adenocarcinoma?

How do you decide between Neoadjuvant (Checkmate 816) and Peri-adjuvant (Keynote 671) chemoimmunotherapy for early stage NSCLC?

What are your top takeaways from ESMO 2023?

Will you consider definitive concurrent chemoradiation for stage IV lung adenocarcinoma with metastasis limited to an internal mammary lymph node?

Which targeted therapies should we be more cautious of giving after recent immunotherapy in NSCLC?

Would you ever consider repeating chemoradiation for patients with locally recurrent small cell lung cancer after prior chemoradiation for LS-SCLC?

What are your top takeaways in Thoracic Cancers from ASCO 2023?

How are you approaching patients who receive neoadjuvant chemo immunotherapy for resectable NSCLC who after completion of neoadjuvant treatment are no longer surgical candidates due to factors such as toxicity, decline in PS, or patient preference?